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Abstract: Mitochondrial fusion is essential to mitochondrial fitness and cellular health. Neurons of patients with genetic neurodegenerative diseases often exhibit mitochondrial fragmentation, reflecting
an imbalance in mitochondrial fusion and fission (mitochondrial dysdynamism). Charcot–Marie–
Tooth (CMT) disease type 2A is the prototypical disorder of impaired mitochondrial fusion caused
by mutations in the fusion protein mitofusin (MFN)2. Yet, cultured CMT2A patient fibroblast mitochondria are often reported as morphologically normal. Metabolic stress might evoke pathological
mitochondrial phenotypes in cultured patient fibroblasts, providing a platform for the pre-clinical
individualized evaluation of investigational therapeutics. Here, substitution of galactose for glucose
in culture media was used to redirect CMT2A patient fibroblasts (MFN2 T105M, R274W, H361Y,
R364W) from glycolytic metabolism to mitochondrial oxidative phosphorylation, which provoked
characteristic mitochondrial fragmentation and depolarization and induced a distinct transcriptional
signature. Pharmacological MFN activation of metabolically reprogrammed fibroblasts partially
reversed the mitochondrial abnormalities in CMT2A and CMT1 and a subset of Parkinson’s and
Alzheimer’s disease patients, implicating addressable mitochondrial dysdynamism in these illnesses.
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1. Introduction
Mitochondria are descendants of bacterial endosymbionts that took up residence in
primitive unicellular organisms approximately 1.5 billion years ago [1]. As such, mitochondria retain some characteristics of their bacterial ancestors, including partial genomes
(mtDNA) and processes that repair and replicate those genomes. Mitochondrial genome
repair relies heavily upon the intermixing of mtDNA and other contents from different
individual organelles through mitochondrial fusion [2]. Mitochondrial quality control
and replication require the reciprocal response, mitochondrial fission [3]. An imbalance
between mitochondrial fusion and fission (dysdynamism), typically favoring fission and
therefore provoking “mitochondrial fragmentation”, is a common feature of many neurodegenerative diseases. It is postulated that mitochondrial dysdynamism plays causal or
contributory roles in such conditions [4,5].
Mitochondrial fusion and fission are mediated by dynamin family GTPases. Dynaminrelated protein 1 (DRP1) is the major effector of mitochondria fission [6]; DRP1 mutations
are a cause of rare severe neurological disease [7,8]. Mitofusins (MFN) 1 and 2 and Optic
atrophy 1 (OPA1) are the effectors of mitochondrial fusion. MFNs mediate the initial steps
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of outer membrane tethering and fusion, whereas OPA1 is the effector of subsequent inner
membrane fusion [2]. OPA1 mutations can cause dominant optic atrophy [9,10], while many
MFN2 mutations cause the peripheral sensory–motor neuropathy Charcot–Marie–Tooth
disease type 2A (CMT2A) [7,8,11].
It has frequently been observed that neurons, but not fibroblasts, from patients with
CMT2A and other neurodegenerative diseases exhibit mitochondrial fragmentation, leading to the hypothesis that fibroblasts are resistant, and neurons especially sensitive, to
mitochondrial dysdynamism [12–14]. Here, we examined the counterhypothesis that patient fibroblasts do not exhibit disease-related mitochondrial phenotypes because they are
metabolically quiescent under typical culture conditions. After inducing mitochondrialdependent respiration through substrate switching, mitochondrial fragmentation or depolarization was observed in some, but not all, of several representative genetic and
etiologically diverse neurodegenerative diseases. These results suggest an individualized
approach to the evaluation of mitochondrial pathology and responsiveness in preclinical
experimental systems.
2. Materials and Methods
Primary human fibroblasts from CMT2A patients (MFN2 Thr105Met and MFN2 His361Tyr)
were obtained from Dr. Robert Baloh (Department of Neurology, Cedars-Sinai Medical
Center, Los Angeles, CA USA), MFN2 Arg364Trp were from Dr. Michael Shy (Department of Neurology, University of Iowa), and MFN2 Arg274Trp were from Dr. Barbara
Zablocka (Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw,
Poland). Primary human fibroblasts from Parkinson disease (PARK2 Arg275Trp: ND29969,
PINK1 Ile368Asn: ND40066, LRRK2 Gly2019Ser: ND33879), Alzheimer’s disease (PSEN1
Met146Ile: ND34732, Glu184Asp: ND34730, Pro264Leu: ND34733), and normal individuals
(Normal 1: ND34769, Normal 2: ND36320, Normal 3: ND29510) were purchased from
the NINDS Human Cell and Data Repository. CMT1A PMP22 DUP patient fibroblasts
(ID: GM05167) were purchased from the Coriell Institute, USA. Human fibroblasts were
maintained in DMEM supplemented with 15% (v/v) FBS (Gibco, Cat#: A4766801) and 1%
(v/v) penicillin/streptomycin (Gibco, Cat#: 15140122) at 37 ◦ C in 5% CO2 –95% air. Prior to
live-cell studies, fibroblasts were plated on glass coverslips and transitioned to no-glucose
DMEM from Thermo Fisher Scientific (Waltham, Cat#: A1443001) with 4.5 g/L galactose
(Sigma, Cat#: SLBP0699V), 1% FBS, 5 mM sodium pyruvate from Thermo Fisher Scientific
(Waltham, Cat#: 11360-070) and 2 mM L-glutamine from Corning (Corning, Cat#: 34717007)
and treated with Chimera (100 nM/24 h) or DMSO for 48 h [15].
Live-cell studies assessing mitochondrial morphology and polarization status were performed
essentially as described [14]. Human fibroblasts were triple-stained with MitoTracker Green
(200 nM, Invitrogen, Thermo Fisher Scientific, Cat#: M7514) to visualize mitochondria,
tetramethyl rhodamine ethyl ester (TMRE, 200 nM, Invitrogen, Thermo Fisher Scientific
Cat#: T-669) that labels mitochondria with intact polarization of the mitochondrial inner
membrane), and Hoechst (10 ug/mL, Invitrogen, Thermo Fisher Scientific, Cat#: H3570)
that stains nuclei in blue. Images were acquired at room temperature on a Nikon Ti
Confocal microscope using a 60 × 1.3 NA oil-immersion objective, in HEPES-buffered
Krebs–Henseleit solution (138 mM NaCl, 3.7 mM KCl, 1.2 mM KH2 PO4 , 1 mM CaCl2 ,
15 mM glucose, 20 mM HEPES, pH: 7.4). Laser excitation was at 488 nm with emission at
510 nm for MitoTracker Green, 549 nm with emission at 590 nm for TMRE, and 306 nm
with emission 405 nm for Hoechst. Images were analyzed using Image J.
Fusogenicity was quantified as an increase in mitochondrial aspect ratio (length/width).
Mitochondrial dimensions from MitoTracker Green-stained confocal micrographs were
measured using the Image J freehand line measurement tool [14]. Approximately
30 mitochondria per cell were measured in 12–15 cells in each independent experiment.
Mitochondrial depolarization (%) was determined as the number of depolarized (negative
red TMRE-stained) mitochondria relative to the total number of mitochondria (MitoTracker
Green-stained) in each cell. Since red TMRE overlayed with MitoTracker Green mito-
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chondria appears yellow in merged images, yellow mitochondria are fully polarized, and
green mitochondria are depolarized [14]. Over 100 mitochondria per cell were counted in
MitoTracker Green and TMRE merged images using the Image J multi-point tool. Approximately 12–15 cells were measured in each experiment, and the results were averaged to
represent a single experimental n.
mRNA sequencing library preparation and analysis used total RNA from human fibroblasts, isolated with TRIzol Reagent (Ambion RNA Life technologies, Cat#: 15596-026,) and
treated with DNase I (Invitrogen, Cat#: 18068015). mRNA sequencing was performed
at the Genome Technology Access Center (GTAC) Washington University St. Louis, MO
(USA) using the RiboErase protocol, with indexing and pooled sequencing on a NovaSeq
S4. Sequencing depth was 30M reads per sample. RNA-seq reads were aligned to the
Homo sapiens-hg19_chr22 assembly with STAR. Refseq was used as the annotation model
to quantify gene counts and then normalized to CPM (counts per million). Pair-wise
comparisons between transcriptomic profiles from each experimental group were analyzed
using the GSA method in Partek Flow and filtered a priori (CPM (Counts per Million) ≥ 10
for at least one biological sample, p value < 0.05, fold change > (±) 1.5). Unsupervised
hierarchical clustering using Euclidean distance and average distance was performed using
Partek Flow. Pathway analyses used Database for Annotation, Visualization and Integrated
Discovery (DAVID v6.8). The GEO accession number is GSE158650.
Statistical analysis and data reporting used one- or two-way analysis of variance (ANOVA)
for multi-group comparisons. The t-test was used for comparisons of two groups; p < 0.05
was considered as significant. Data are reported as independent experiments, each averaging results of 8–15 cells, expressed as mean ± standard error.
3. Results
3.1. Substrate Switching Induces Mitochondrial Pathology in Cultured CMT2A
Patient Fibroblasts
CMT2A is a progressive, largely pediatric non-demyelinating peripheral sensory–
motor neuropathy caused by genetic mutations in the mitochondrial fusion protein mitofusin (MFN) 2 [7,8,11]. Neuronal die-back from chronic mitochondrial dysfunction evokes
neurogenic muscular atrophy of the distal upper and lower extremities. Mitochondrial
fragmentation from defective fusion is one of the prototypical features of CMT2A neurons and is recapitulated in fibroblasts derived from mice with genetic ablation of MFN2
or MFN1 [12–14]. However, the published descriptions of mitochondrial phenotypes in
CMT2A patient dermal fibroblasts are inconsistent [16,17]. Metabolic substrate switching
that forces fibroblasts to use mitochondrial oxidative phosphorylation rather than nonmitochondrial glycolysis [18,19] previously induced mitochondrial shortening and other
phenotypes in fibroblasts from a CMT2A patient carrying the MFN2 R274W mutation [20].
Therefore, we generalized this approach and examined the effects of substrate switching
on four different CMT2A mutant cell lines.
Cultured dermal fibroblasts from a normal subject had normal mitochondrial morphology and polarization status, neither of which were affected by glucose or galactose
substrate present in the culture medium (Figure 1A,B,D). Likewise, fibroblasts from CMT2A
MFN2 T105M, R274W, H361Y, and R364W mutation patients cultured under standard conditions with glucose exhibited normal mitochondrial morphology and polarization status
(Figure 1B–D). Strikingly, replacing glucose that is readily metabolized by mitochondrialindependent glycolysis, with galactose, which is not a facile substrate for glycolysis but
is used by mitochondria for oxidative phosphorylation [18,19], provoked characteristic
mitochondrial fragmentation and dissipation of the mitochondrial inner membrane electrochemical gradient, ∆ψm (Figure 1C,D) [12]. Moreover, as depicted in Figure 2, CMT2A
fibroblasts cultured in galactose developed a distinct transcriptional signature characterized
by increased levels of mRNAs linked to neuron development (green) and programmed cell
death (purple), and decreased levels of mRNAs involved in metabolic (blue) and biosynthetic (orange) processes. Thus, forcing mitochondrial respiration by metabolic substrate
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switching induced pathological morphological, functional, and transcriptional phenotypes
in multiple CMT2A MFN2 mutant fibroblasts.

Figure 1. Redirecting fibroblast metabolism with galactose provokes mitochondrial pathology in CMT2A.
(A,C). Representative confocal images of normal (A) and CMT2A (MFN2 T105M) patient (C) fibroblasts cultured in glucose or galactose; Mito Tracker Green (green), TMRE (red), Hoechst (blue).
Insets show images further magnified for clarity. Healthy mitochondria are yellow/orange; depolarized mitochondria are green. Scale bars are 10 microns. (B,D). Quantitative group data for
normal and CMT2A patient fibroblast mitochondrial aspect ratio (B) and depolarization (D). Data are
means ± SEM; statistics by two-way ANOVA, p values are at the top of the bars. NS = Nonsignificant.
The number of independent experiments is shown on the bottom of each bar.
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Figure 2. CMT2A patient fibroblasts have a distinct transcriptional signature. (A) Heat map results for
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Since we found that CMT2A-associated mitochondrial phenotypes could be provoked
Since we
found that CMT2A-associated mitochondrial phenotypes could be proin cultured patient fibroblasts, we asked if this experimental platform could be used to test
voked in cultured patient fibroblasts, we asked if this experimental platform could be used
the potential efficacy of an investigative therapeutic strategy through in vitro phenotype reto test the potential efficacy of an investigative therapeutic strategy through in vitro pheversal. Chimera is a prototype small-molecule mitofusin activator that reportedly improved
notype reversal. Chimera is a prototype small-molecule mitofusin activator that reportmitochondrial dysmorphology and dysfunction produced by Mfn gene ablation in mouse
edly improved mitochondrial dysmorphology and dysfunction produced by Mfn gene
fibroblasts [14,21]. Here, Chimera (100 nM, 48 h) reversed mitochondrial fragmentation and
ablation in mouse fibroblasts [14,21]. Here, Chimera (100 nM, 48 h) reversed mitochondepolarization in four genetically distinct metabolically stressed CMT2A patient fibroblast
drial fragmentation and depolarization in four genetically distinct metabolically stressed
lines (Figure 3A,B, left graph).
CMT2A patient fibroblast lines (Figure 3A,B, left graph).
CMT type 1 is an adult peripheral neuropathy commonly caused by duplication mutations in the myelin-associated PMP22 gene. CMT1 is a demyelinating disease of neuronassociated Schwann cells [22], which contrasts with CMT2A that is a primary disease of
neuronal mitochondria. The mechanistic basis for mitochondrial abnormalities in CMT1
is not fully understood [23]. Here, fibroblasts from a CMT1 patient developed modest mitochondrial fragmentation after galactose substitution, which was improved by Chimera
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(Figure 3A,B top panels, right graph), and mild mitochondrial hypopolarization on which
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Chimera had no effect. (Figure 3A,B, bottom panels, right graph).
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by mutations in PINK1 or PARK2 (Parkin) mitophagy genes. Selective loss
dopaminergic neurons in the substantia nigra and locus coeruleus causes progressive motor
dysfunction, most typically bradykinesia and resting tremor. Because mitophagy, sensed by
PINK1 and effected by Parkin, is critical for mitochondrial quality control, Parkinson’s dismitochondrial disorder [24]. Thus, we evaluated mitochondrial phenotypes in Parkinease caused by mutations of these genes is widely considered a mitochondrial disorder [24].
son’s disease patients’ fibroblasts carrying mutations in PINK (I368N), PARK2 (R275W),
Thus, we evaluated mitochondrial phenotypes in Parkinson’s disease patients’ fibroblasts
and the most common Parkinson’s disease gene, LRRK2 (G2019S). Galactose induced a
carrying mutations in PINK (I368N), PARK2 (R275W), and the most common Parkinson’s
modest, but statistically significant, reduction in the mitochondrial aspect ratio only in
disease gene, LRRK2 (G2019S). Galactose induced a modest, but statistically significant,
LRRK2 and PARK2 mutant fibroblasts (Figure 4A, left), but provoked mitochondrial dereduction in the mitochondrial aspect ratio only in LRRK2 and PARK2 mutant fibroblasts
polarization in all three Parkinson’s disease cell lines (Figure 4A, right). Mitochondrial
(Figure 4A, left), but provoked mitochondrial depolarization in all three Parkinson’s disease
fragmentation and mitochondrial depolarization were improved by Chimera only in
cell lines (Figure 4A, right). Mitochondrial fragmentation and mitochondrial depolarization
PARK2 mutant cells (Figure 4A,B).
were improved by Chimera only in PARK2 mutant cells (Figure 4A,B).
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3.4. Mitochondrial Pathology Is Variable in Fibroblasts from Alzheimer’s Diseases Individuals
3.4. Mitochondrial Pathology Is Variable in Fibroblasts from Alzheimer’s Diseases Individuals
Early-onset familial Alzheimer’s disease (AD) is a progressive dementia that can be
Early-onset
familial
disease (AD)
a progressive
dementia
that can be
caused
by mutations
in theAlzheimer’s
presenilin (PSEN1]
gene, is
among
others [25].
We characterized
caused
by
mutations
in
the
presenilin
(PSEN1]
gene,
among
others
[25].
We
characterized
fibroblasts from AD patients with three different PSEN1 mutations. Although mitochonfibroblasts
from ADhas
patients
with three
different
mutations.
mitochondrial
fragmentation
been reported
in AD
patientPSEN1
fibroblasts
[25], it Although
was not observed
in
drial fragmentation has been reported in AD patient fibroblasts [25], it was not observed
in our fibroblast lines under these conditions (Figure 5A, white). Moreover, mitochondrial
depolarization was milder and more variable than in CMT2A and CMT1 cells, and Chimera affected only PSEN1 P264L cells (Figure 5B, black).
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our fibroblast lines under these conditions (Figure 5A, white). Moreover, mitochondrial
depolarization was milder and more variable than in CMT2A and CMT1 cells, and Chimera
affected only PSEN1 P264L cells (Figure 5B, black).
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phenotypes in
in primary
primary patients’
patients’
In
vitro
In
mitochondrial phenotypes
cells has
has the
the potential
potential to reveal common mechanisms
mechanisms and predict individual therapeutic
therapeutic
cells
responses. Fibroblasts
Fibroblasts were
were the
the mammalian
mammalian research
research platform
platform of
of choice
choice for
for foundational
foundational
responses.
studies leading
leading to
to the
the current
current understanding
understanding of
of mitochondrial
dynamics [12,26,27].
[12,26,27]. The
The
studies
mitochondrial dynamics
failure
of
most
previous
studies
to
detect
characteristic
mitochondrial
dysmorphology
and
failure of most previous studies to detect characteristic mitochondrial dysmorphology
dysfunction
in
CMT2A
patient-derived
fibroblasts
[16,17,28]
shifted
the
focus
of
recent
and dysfunction in CMT2A patient-derived fibroblasts [16,17,28] shifted the focus of repre-clinical
investigations
to neurons
in which
mitochondrial
dysmotility
can can
affect
cell
cent
pre-clinical
investigations
to neurons
in which
mitochondrial
dysmotility
affect
viability.
However,
iPS
cell-derived
neurons
also
lose
prototypical
CMT2A
mitochondrial
cell viability. However, iPS cell-derived neurons also lose prototypical CMT2A mitochonphenotypes
[16,29].
drial
phenotypes
[16,29].
Because
cultured
fibroblasts are
are metabolically
metabolically hypoactive
hypoactive and
and rely
rely primarily
primarily upon
upon
Because cultured fibroblasts
glycolysis
for
energy
production
[19],
we
considered
that
mitochondrial
metabolic
activity
glycolysis for energy production [19], we considered that mitochondrial metabolic activity
at levels
levels closer
closer to
to those
those encountered
encountered in
in vivo
vivo might
might be
be required
required to
to manifest
manifest characteristic
characteristic
at
disease-related
abnormalities.
This
can
be
accomplished
by
depriving
cultured
cells of
of aa
disease-related abnormalities. This can be accomplished by depriving cultured cells
preferred glycolytic substrate (glucose) and substituting it with a substrate for oxidative
preferred glycolytic substrate (glucose) and substituting it with a substrate for oxidative
phosphorylation (galactose) [18], as previously demonstrated in ALS [15] and CMT2A
phosphorylation (galactose) [18], as previously demonstrated in ALS [15] and CMT2A
MFN2 R274W [20]. This simple maneuver induced mitochondrial fragmentation and loss
MFN2 R274W [20]. This simple maneuver induced mitochondrial fragmentation and loss
of polarization in most (but not all) of the diseased cells studied and in none of the control
of polarization in most (but not all) of the diseased cells studied and in none of the control
subjects’ fibroblast lines.
subjects’ fibroblast lines.
Pharmacological mitofusin activation [14] represents a new therapeutic approach
that can enhance overall mitochondrial health by directly stimulating mitochondrial fusion. Chimera corrected the mitochondrial fragmentation and depolarization in CMT2A
cells with four different MFN2 mutations. The ability of Chimera to reverse mitochondrial
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Pharmacological mitofusin activation [14] represents a new therapeutic approach that
can enhance overall mitochondrial health by directly stimulating mitochondrial fusion.
Chimera corrected the mitochondrial fragmentation and depolarization in CMT2A cells
with four different MFN2 mutations. The ability of Chimera to reverse mitochondrial
phenotypes in CMT2A patients’ fibroblasts reportedly derives from its activation of normal
endogenous MFN1 and MFN2 [14,21]. Thus, by overcoming the dominant suppression
by MFN2 mutants, mitofusin activation helps to restore a more normal balance between
mitochondrial fusion and fission.
All four of the CMT2A MFN2 mutant fibroblast lines studied herein exhibited mitochondrial fragmentation and dissipation of inner membrane polarization when cultured
in galactose, as well as reversal with pharmacological mitofusin activation. However, in
comparison to the other three CMT2A lines, these mitochondrial abnormalities were less
severe in MFN2 R364W cells. The only other published functional report of this mutant
concluded that it enhanced mitochondrial fusion, compared to the GTPase mutants R94Q
and T105M that inhibited fusion [30]. Our data do not agree with the conclusions that
MFN2 R364W is a gain-of-function mutation and that “excessive mitochondrial fusion
drives CMT2A pathogenesis in a large number of patients” [30]. Indeed, these conclusions
were subsequently retracted [30]. Rather, the current data in human CMT2A fibroblasts
and published data in reprogrammed human motor neurons [31] lead us to conclude that
MFN2 R364W is a partial loss-of-function mutant that has haploinsufficiency of MFN2
function but can nevertheless dominantly inhibit mitochondrial fusion promoted by normal MFN1 and MFN2. Importantly, the same data demonstrate unequivocally that, in the
genetic context of clinical CMT2A, MFN2 R364W dysfunction is correctable by allosteric
mitofusin activation. This result refutes another (retracted) conclusion in the Fissi paper:
“Our data also indicate that anti-fission or pro-fusion drugs, envisioned as treatments
for CMT2A or neurodegenerative disease, could be detrimental for patients with R364W
and L76P alleles that would rather benefit from the development of pro-fission or antifusion molecules.” [30]. Here, the pro-fusion mitofusin activator corrected mitochondrial
abnormalities.
We think it likely that weak intrinsic fusogenic activity of MFN2 R364W is similar to
that previously described for MFN2 mutants at amino acids M376 or S378 [14]. Expression
of MFN2 M376A or S378D in murine fibroblasts lacking endogenous MFN1 and MFN2
evokes mitochondrial elongation that is only about one-third as robust as wild-type MFN2
but normalizes after pharmacological mitofusin activation [14]. In the case of the M376
and S378 mutants, impairment of fusogenic activity (as opposed to complete abrogation
caused by GTPase mutants) was the consequence of reduced conformational plasticity [14].
It is notable that, like MFN2 M376 and S378, MFN2 R364 is within the sequence of the
MFN2-derived allosteric activating peptide designated “MP1” that binds to and interrupts
the peptide–peptide interactions that critically determine MFN conformation and therefore
activity [13]. Together with the current findings, this raises the possibility that MFN2
R364W may activate a similar conformational mechanism of functional impairment. It
remains unclear whether actual gain-of-function (as opposed to partial loss-of-function)
MFN2 mutations exist in nature and cause CMT2A.
There are no prior data assessing whether mitofusin activation can reverse pathological mitochondrial phenotypes in conditions not caused by mitofusin defects, such
as CMT1, PD, and AD. Our results show that mitofusin activation generally improves
mitochondrial dysmorphology and respiratory dysfunction when there are underlying
mitochondrial fragmentation and depolarization. Benefits of promoting mitochondrial
fusion were observed in diseases with no known primary abnormalities of mitochondrial
dynamics factors or even of mitochondrial proteins. Nevertheless, as reviewed in detail in
the accompanying companion article [32], our findings raise the possibility that mitofusin
activation and other techniques that normalize fusion–fission imbalances [15,33] can have
therapeutic value beyond primary disorders of mitochondrial dysdynamism.
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